“Loved it, such an eye opener on the future of medicine and benefits of PBMT and what it can do…..Really did enjoy it.”
Regards
Dan George
Hyperbaric Cryo & Altitude Therapy founder
Douglas, Queensland, Australia
View current photobiomodulation therapy training dates in your location.
Jesse Apiti has been wheelchair bound, paralysed from the waist down with a spinal injury since a workplace accident and experienced quite severe nerve pain in the groin area.
Photobiomodulation treatment started 6 months after the accident at ATP Therapy and Jesse has been getting more sensation in his hip areas and pain has gone so can sleep at night.
View current photobiomodulation therapy training dates in your location.
Emily Waters has suffered chronic debilitating back pain for the past 4 years until trying Photobiomodulation at ATP Therapy. Read Emma’s full story below the video.
“22nd of December 2012 was the date my life changed and not for the better. I had gone to a work party; I had arrived late as I didn’t really want to be there, everyone had been drinking a lot. I was there an hour maybe less when I got up to go to the toilet, when I came back I went to sit down in my chair, and one of my co-workers pulled my chair away. I landed on concrete on my bottom, I could tell straight away what had happened had caused permanent and serious damage, it felt as if my spine had been compacted. I was in shock that someone would do something so stupid to me. Continue reading
Dr Hisham Abdalla from Light Spa NZ interviews James Carroll CEO, Founder and Inventor of Thor Photomedicine and the NovoTHOR light-pod.
James Carroll shares visions, science, evolution and the future of PhotoBiomodulation and Light/laser therapies, as well as James’s recent achievements at the US Congress and The United Nations.
View current photobiomodulation therapy training dates in your location.
A hundred million adults in the United States are affected by chronic pain and $600 billion a year is spent on in health care, direct health care costs and lost productivity because of pain.
49,000 people from opioids in 2017, 19,000 of which were from prescribed opioids for pain relief.
We believe that Photobiomodulation therapy can help reduce the prescribing of opioid medication for pain relief and we wish to draw attention to the Congress and health care policymakers, NIH and CMS, about this potentially valuable tool.
Learn more at CongressPBM.com
Watch the Congressional Briefing Highlight Video
Read James Carroll’s Speech to Congress on citizenoversight.blogspot.com
View current photobiomodulation therapy training dates in your location.
LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI).
The phase II grant supports a prospective, randomized, multi-center human clinical trial in U.S. subjects diagnosed with dry age-related macular degeneration (dry AMD.) The LIGHTSITE III trial, which is subject to FDA Investigational Device Exemption (IDE) approval, will test vision and examine disease pathology in the eye following PBM treatments using the Company’s Valeda™ Light Delivery System. Subjects will be followed for up to two years. In 2018, LumiThera obtained a CE mark to commercialize the Valeda™ Light Delivery System in Europe for the treatment of dry AMD. A companion post-marketing study (LIGHTSITE II) is being readied for Europe.
“Dry AMD is one of the largest unmet medical needs in medicine and its prevalence is increasing as we live longer,” commented Quan Dong Nguyen, M.D., M.Sc. and Diana V. Do, M.D., both professors of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. “In ophthalmology, currently, we have no therapies that can be offered to these patients. Both of us and many of our colleagues at Stanford, in the US, and throughout the world recognize the potential that PBM could provide as an early treatment for dry AMD, and if so, can bring significant benefits to millions of patients globally.”
“The LIGHTSITE II and III trials are part of LumiThera’s global efforts to bring forward a treatment for a debilitating eye disease that results in central loss of vision,” stated David Boyer, MD., Retina-Vitreous Associates Medical Group, Los Angeles, CA. “The planned European and US trials would create a novel treatment option for dry AMD patients, who currently have limited choices.”
“The NIH clinical grant is substantial in providing over $2.5M in funding to develop a PBM therapy for dry AMD patients in the U.S.,” stated Clark Tedford, Ph.D., President and CEO. “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera, and the grant is a significant step in the validation of the PBM technology and its potential in treating chronic eye disease.”
“We are very excited to be part of the LIGHTSITE U.S. multicenter trial.” remarked Richard Rosen, M.D., New York Eye and Ear Infirmary of Mount Sinai. “Several major U.S. centers are participating in this trial, which should help substantiate the clinical benefits of this therapy, reported to date. This trial will measure a variety of clinical and pathological outcomes and establish the long-term benefits of PBM for dry AMD patients.”
View the press release on Lumithera website at www.lumithera.com
Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.
U.S. CONGRESSIONAL BRIEFING. Ending Opioid Use – Washington DC
James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.
Learn more at CongressPBM.com
Watch James Carroll’s Congress speech on ending opioid use with Photobiomodulation
Read James Carroll’s Speech to Congress on citizenoversight.blogspot.com
View current photobiomodulation therapy training dates in your location.
36 Photobiomodulation therapy papers published in February 2018. Highlights include:
This 15 minute video starts with an overview of Photobiomodulation and low level light therapy. Later in the presentation James introduces the Lumithera treatment for Dry Age related Macular Degeneration (AMD).
The paper “High-intensity versus low-level laser therapy in the treatment of patients with knee osteoarthritis: a randomized controlled trial” Kheshie et al 2014 pitches the 3B BTL laser against the HIRO class IV “High intensity” laser. The results appear to show that the HIRO class IV “High intensity laser” was more effective than the “Low Level Laser”. HOWEVER, the HIRO class IV “High intensity” laser was delivered over a large area (not adequately defined but approx 100cm2 by my estimation) so the intensity was actually very low (about 13mW/cm2 which is less than most LED systems), and the 3B BTL “Low Level Laser” was actually very high (4 x 200mW small, high intensity beams) and were held stationary on the patella for over half an hour, YES, HALF AN HOUR IN ONE SPOT! This is insane.
This paper leads people to think that the class IV Hiro laser was more effective because it was higher intensity when in fact the beam distribution meant the average intensity distribution was low (13mW/cm2). The 3B laser was not so effective because it was held stationary such that it would cause an overdose. If the 3B laser treatment had been delivered in using same scanning technique as the class IV then they would likely have achieved the same result. (I am not a fan of scanning because you can never be sure how much energy you have delivered to an area, better to use a low intensity device and hold it still in my view).
This paper misdirects the reader towards favouring class IV lasers rather than 3b or LED by misinforming the reader.
The title of last months PMLS editorial was Low Level Laser Therapy (LLLT) and World Association for Laser Therapy (WALT) Dosage Recommendations. Written by the Scientific Secretary Prof. Jan Bjordal. He describes how far we have come and the importance of the WALT dosage recommendations. No abstract is available for editorials so I have prepared one for you below. Continue reading
A paper titled ”The Effectiveness of Therapeutic Class IV (10 W) Laser Treatment for Epicondylitis” [ref] showed that 10 Watt Class IV laser (mixed 8W 970nm, 2W 810) was successful in reducing pain and improving function in an RCT with 15 patients, and that there was good statistical significance at 6 months following a course of 6 treatments.
The claim by class IV laser manufacturers is that class IV lasers are better (faster, deeper and more effective) than Class 3b and LED systems. Conversely the 3B laser and LED manufacturers argue that less power density is more effective because delivering energy too quickly can overdose tissues and class IV lasers might burn the skin.
Throughout this paper there are marketing messages claiming the advantages of shorter treatment times than low power LLLT systems and of course the title shouts “10 Watt Class IV laser” just in case the reader is in any doubt that more power is what you need.
Regular readers of this column know my obsession with irradiation parameters, particularly dose rate effects (W/cm2) and will not be surprised to learn that I deconstruced the irradiation parameters used in this trial . Surprise, surprise they were the same low irradiance levels typically used by 3B lasers and LED systems, if not less and the treatment time was longer too.
Yes, it was a 10 Watt laser and yes, 3,000 joules was delivered, however it had a large beam area and treatment was delivered over (45cm2) in a “painting fashion”. The fluence (dose) was 6.6 Joules/cm2 and the power density was a tiny 22mW/cm2, consequently treatment time was a hefty 5 mins.
The average irradiance was not disclosed in the paper and the reader is directed to think that more power is quicker.
P.S. research trials with 3B lasers are typically 30 seconds to 3 mins and our recommended treatment is 1 min with a large LED cluster to the lateral epicondyle and 30 seconds for any related trigger points.
Available only to THOR Customers and/or people who have attended a THOR training course in the last 3 years. All treatments are based on our four step method which includes treatment of the injury, trigger points, lymphatics and nerve roots.
Take a look to see how it works and let us know what you think.
Access Treatment Protocol Library
Chris had tried many different therapies for her health issues and after using NovoTHOR at Immortality OC she feels the difference and hasn’t felt this good in a really long time.
View current photobiomodulation therapy training dates in your location.
“The course was a great refresher. It was good to have the understanding of the physics and be able to concentrate on the Photobiomodulation aspect of the course.
Thanks again”
Dr Lynn Lamon
Dentist
New Brunswick, Canada
View current photobiomodulation therapy training dates in your location.
“This company leads with research and science, not salesmanship and gimmicks, and that’s the reason that I originally decided to purchase the Thor laser.
The seminars are practical and offer information that is both interesting and clinically relevant. I look forward to attending future seminars, and I highly recommend the Thor Laser to anyone who is considering the purchase of a laser.”
Dr. Darren Bell
Chiropractor
New York, USA
View current photobiomodulation therapy training dates in your location.
UK and Ireland dates
USA and Canada dates
Australia and NZ dates
Rest Of World dates
Featured Testimonials
THOR on Facebook
THOR on Twitter
THOR on LinkedIn
THOR on Instagram
THOR on YouTube